ARWR

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Arrowhead's experimental RNAi drug shows potential for Alzheimer's disease as a subcutaneous treatment reaches the brain and sharply reduces a disease-linked proteinOct 18, 2026
• Arrowhead Pharmaceuticals reports interim Phase 1/2a ARO-MAPT data showing deep and sustained tau reductions in healthy volunteersOct 14, 2026
• Arrowhead Pharmaceuticals reported interim topline clinical data for its first dual-functional RNAi therapy for mixed hyperlipidemiaSep 15, 2026
• Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data showing plozasiran reduced acute pancreatitis events in patients with severe hypertriglyceridemiaAug 31, 2026
• Arrowhead Pharmaceuticals licensed its clinical MASH program targeting PNPLA3 to Madrigal PharmaceuticalsMay 5, 2026